Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 23, 2006

View Archived Issues

Heidelberg Pharma report on improved efficacy of novel alovudine prodrug

Targeting PKC beta for the treatment of diabetic cardiomyopathy

Emerging targets and molecular markers in head and neck cancer

Phase I findings for RP-101 with gemcitabine in advanced pancreatic cancer

Expiration dates confirmed and new agreement for golimumab

Vicriviroc demonstrates potent and sustained viral suppression in HIV

Milestone in collaboration between Ortec and ES Cell International

TAFA-93 shows promise in phase I studies

Japanese marketing alliance discontinued for Ketek

QD-3: a novel peptidic HIV-1 fusion inhibitor for drug-resistant viruses

Preclinical studies confirm that bevirimat is non-teratogenic

Aptivus/ritonavir efficacious and safe in PI-resistant pediatric patients

Recent Dainippon patent describes new treatment option for cardiovascular disorders

Recent patents disclose new therapeutic agents for anxiety, depression, etc.

Novel antidiabetic compounds disclosed by Sirtris in recent patent

New Schering patent describes therapeutic agents for allergic and respiratory disorders

Glypromate shows good pharmacokinetic profile

CoGenesys and Vegenics sign VEGF licensing agreement

Stromectol approved in Japan for treatment of scabies

Alnylam grants Calando license under InterfeRx program

Canadian approval for Azilect in Parkinson's disease

ATG-003 begins phase I testing for AMD

Dynavax's ISS vaccine shows potential as universal flu vaccine

ASF-1075 studied for psoriasis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...